Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Eli Lilly
>
FDA tells Eli Lilly it can quickly refile NDA for hopeful Baricitinib
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="RobertPhillips900, post: 5918458, member: 30268"]Lilly will resubmit the New Drug Application for rheumatoid arthritis medication baricitinib, to the U.S. Food and Drug Administration (FDA), before the end of January 2018. The companies anticipate the FDA will classify the application as a Class II resubmission, which will start a new six-month review cycle. <a href="http://alph.st/b283c853" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://alph.st/b283c853" rel="nofollow">http://alph.st/b283c853</a>[/QUOTE]</p><p><br /></p>
[QUOTE="RobertPhillips900, post: 5918458, member: 30268"]Lilly will resubmit the New Drug Application for rheumatoid arthritis medication baricitinib, to the U.S. Food and Drug Administration (FDA), before the end of January 2018. The companies anticipate the FDA will classify the application as a Class II resubmission, which will start a new six-month review cycle. [URL]http://alph.st/b283c853[/URL][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Eli Lilly
>
FDA tells Eli Lilly it can quickly refile NDA for hopeful Baricitinib
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Eli Lilly
>
FDA tells Eli Lilly it can quickly refile NDA for hopeful Baricitinib
>